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Objectives: Vascular comorbidities (diabetes, hyperten-
sion, coronary disease and hyperlipidemia) cause vascular
cognitive impairment (VCI). The Asymptomatic Carotid Ste-
nosis and Cognitive Function (ACCOF) study is the ﬁrst
attempt to identify the isolated impact of asymptomatic ca-
rotid stenosis (ACS) on cognitive function; stenosis patients
were compared to patients with similar vascular comorbidities
but no stenosis. Cerebrovascular hemodynamic characteristics
were analyzed to elucidate mechanisms impacting cognition
Methods: 69 patients with $50% ACS and 60 con-
trols with vascular co-morbidities without ACS under-
went comprehensive cognitive testing by a trained
neuropsychologist. Scores were adjusted for age, sex, ed-
ucation, and race using normative data. An overall index
of cognitive function and ﬁve domain-speciﬁc scores
were computed. Breath holding index (BHI), an estimate
of cerebrovascular reserve, was measured using transcra-
nial Doppler. Patients were assigned to high vs low BHI
groups using a cut-off score of .69. Independent samples
t-tests were computed to assess cognitive differences
among (a) stenosis vs control patients and (b) stenosis pa-
tients with low vs high BHIs. Cohen’s d was calculated to
determine effect sizes.
Results: The stenosis and control groups did not
differ with respect to vascular risk factors, IQ and depres-
sive symptoms. The stenosis group performed worse on
the overall composite cognitive score (t ¼ 2.8; P # .01;
d ¼ .52) and the domain-speciﬁc scores for processing
speed (t ¼ 3.5; P # .01; d ¼ .69) and learning (t ¼
2.6; P # .05; d¼.48). A trend of reduced performance
for executive function and attention emerged (t ¼ 1.3-
1.8; P ¼ .07-.17; d ¼ .26). Within the stenosis group,
those with low BHI performed worse on learning (t ¼
2.4; P < .05; d ¼ .68), processing speed (t ¼ 1.79;
P < .09; d ¼ .42) and overall composite score (t ¼ 2.0;
P <.06; d ¼ .58).
Conclusions: Asymptomatic carotid stenosis is associ-
ated with cognitive impairment when compared to patients
with similar risk factors but no stenosis. The deﬁcit is driven
primarily by reduced processing speed and learning, and is
mild to moderate in severity. A likely mechanism for this
impairment is reduced cerebrovascular reserve. These ﬁnd-
ings have the potential to impact decision-making in the
management of patients with ACS.
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Objectives: Despite improvements in endovascular
therapy for lower extremity arterial disease, open surgical
revascularization is still required when the disease is exten-
sive. While autogenous vein is the conduit of choice for
open femoropopliteal bypass, prosthetic grafts can be an
acceptable alternative when adequate vein is not available.
The FUSION BIOLINETM heparin coated vascular graft
was developed to improve the patency rate associated with
standard prosthetic grafts. The current study (FINEST
Trial) was designed to assess the clinical outcome of hepa-
rin coated and standard vascular grafts in a prospective ran-
domized, controlled, multicenter trial.
Methods: Over a 25-month period ending in June
2012, 209 eligible patients requiring prosthetic femoral to
above or below-knee popliteal bypass were randomized to
receive a standard expanded polytetraﬂuoroethylene
(ePTFE) graft or the heparin coated FUSION BIOLINE
vascular graft (Maquet Cardiovascular, Wayne, NJ). Grafts
were assessed by duplex ultrasound and ankle-brachial
indices, performed at discharge and 30-days, 6-months,
and 12-months postoperatively. The primary efﬁcacy
endpoint was primary patency of the study graft. The primary
safety endpoint was the composite of major adverse events
and periprocedural death. Secondary endpoints included pri-
mary-assisted and secondary patency, as well as the time to
hemostasis of the anastomotic suture hole bleeding.
Results: The 6-month primary patency rate was 86.4%
for the FUSION BIOLINE heparin coated vascular graft
group compared to 70.0% for the standard ePTFE group,
a difference of 16.4% (95% CI, 2.7%-29.9%; P ¼ .006).
At 12-months, the primary patency rates were 76.5% and
67.0% in the two groups, respectively (95% CI, -4.8% to
23.0%; P ¼ .050). The mean time to hemostasis of suture
hole bleeding was 3.5 minutes in the FUSION BIOLINE
group and 11.0 minutes in the standard ePTFE group (P <
.0001). Major adverse events were signiﬁcantly lower in the
FUSION BIOLINE group, occurring in 17.1% compared
with 30.7% of the standard ePTFE group (P ¼ .033), prin-
cipally a result of a lower rate of major graft reinterventions
through 12-months in the FUSION BIOLINE group;
16.2% versus 30.7%.
Conclusions: Data from this randomized multicenter
study demonstrated improved patency, less suture hole
bleeding, and lower major adverse events with the
FUSION BIOLINE heparin coated vascular graft
compared with standard ePTFE grafts. Whether or not
longer-term outcome is improved cannot be ascertained
with the data currently available, but the utility of the
FUSION BIOLINE vascular graft appears very promising.Author Disclosures: A. Lumsden: Consulting fees and
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